Evidence map›Paper›PMID 40305440›Full record

ArticleThe American journal of case reports2025

AMH and Kisspeptin Receptor Expression in Rare Hydropic Leiomyoma: A Case Study.

Marek Gowkielewicz, Aleksandra Lipka, Aleksandra Piotrowska, Marta Szadurska-Noga, Anna Szalcunas-Olsztyn, Maciej Eliszewski, Paweł Radkowski, Piotr Dzięgiel, Tomasz Waśniewski, Marta Majewska

Abstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marek GowkielewiczDepartment of Gynecology and Obstetrics, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.ORCID 0000-0002-3868-1679
Aleksandra LipkaInstitute of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway.ORCID 0000-0003-0815-6635
Aleksandra PiotrowskaDivision of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wrocław Medical University, Wrocław, Poland.ORCID 0000-0003-4093-7386
Marta Szadurska-NogaDepartment of Pathomorphology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.ORCID 0000-0002-1563-7915
Anna Szalcunas-OlsztynDepartment of Radiology and Diagnostic, Regional Specialist Hospital in Olsztyn, Olsztyn, Poland.
Maciej EliszewskiDepartment of Gynecology and Obstetrics, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
Paweł RadkowskiDepartment of Anaesthesiology and Intensive Care, Faculty of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
Piotr DzięgielDivision of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wrocław Medical University, Wrocław, Poland.ORCID 0000-0002-8292-1385
Tomasz WaśniewskiDepartment of Gynecology and Obstetrics, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
Marta MajewskaDepartment of Human Physiology and Pathophysiology, School of Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.ORCID 0000-0001-5856-6929

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Leiomyomas are common benign uterine tumors (BUMTs) with diverse histopathological subtypes and variable clinical presentations. While most are asymptomatic, some cause significant morbidity, including abnormal uterine bleeding, infertility, and pain. Hydropic leiomyomas (HLMs) are rare variants histopathologically characterized by zonal edema and may pose diagnostic challenges, particularly when located in atypical sites such as the retroperitoneal space. This report presents a case of a retroperitoneal HLM with strong expression of anti-Müllerian hormone (AMH) and its receptor (AMHR2), and kisspeptin (KISS1) and its receptor (KISS1R), suggesting potential new therapeutic targets. CASE REPORT A 44-year-old woman presented with acute lower abdominal pain. Magnetic resonance imaging (MRI) revealed a well-circumscribed, pedunculated retroperitoneal mass originating posteriorly from the uterine body-cervix junction. MRI findings suggested a benign mesenchymal tumor but could not exclude malignancy. Surgical excision was performed, and histopathological examination confirmed HLM. Immunohistochemical analysis demonstrated strong nuclear and cytoplasmic expression of AMH, AMHR2, KISS1, and KISS1R in tumor cells, making this the first reported case of such expression in HLM. The patient had an uneventful postoperative course, and no recurrence was observed during a 2-year follow-up. CONCLUSIONS This case underscores the diagnostic complexity of retroperitoneal HLMs and the importance of MRI in differentiating BUMTs from malignancies. Strong AMH, AMHR2, KISS1, and KISS1R expression suggests a potential role of these regulatory proteins in HLM pathophysiology. Further research on targeted modulation of these pathways may provide novel therapeutic approaches for BUMTs, particularly in cases where conventional treatments are limited.

Indexed as

Anti-Mullerian HormoneKisspeptinsLeiomyomaReceptors, Kisspeptin-1Receptors, PeptideUterine NeoplasmsAdultFemaleHumansMagnetic Resonance ImagingReceptors, Transforming Growth Factor betaAnti-Mullerian Hormoneanti-Mullerian hormone receptorKISS1R protein, humanKisspeptinsReceptors, Kisspeptin-1Receptors, PeptideReceptors, Transforming Growth Factor beta

Identifiers

PMID40305440
PMCPMC12051407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.